This is a preview of subscription content, log in via an institution to check access.
References
Padro T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002; 16: 1302–1310.
Gerber HP, Ferrera N . The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003; 57: 4593–4599.
Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857–10862.
Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98: 241–243.
Massa M, Rosti V, Ramajoli I, Campanelli R, Pecci A, Viarengo G et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 5688–5695.
Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005; 105: 3286–3294, E-pub 23 December 2004.
Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-β-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004; 10: 3577–3585.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zahiragic, L., Schliemann, C., Bieker, R. et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 21, 1310–1312 (2007). https://doi.org/10.1038/sj.leu.2404632
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404632
- Springer Nature Limited
This article is cited by
-
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
Annals of Hematology (2023)
-
Hypoxia and Hematopoiesis
Current Stem Cell Reports (2022)
-
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development
Experimental Hematology & Oncology (2021)
-
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)
Annals of Hematology (2019)
-
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features
BMC Cancer (2015)